Blockchain Registration Transaction Record

NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery

NeuroOne partners with University of Minnesota to advance sEEG-based drug delivery for epilepsy, aiming to improve precision and reduce side effects in seizure treatment.

This collaboration matters because it addresses a critical gap in epilepsy treatment by focusing on localized drug delivery, which could significantly reduce systemic side effects and improve precision for patients. Epilepsy affects millions worldwide, and current treatments often involve medications with broad impacts on the body, leading to adverse reactions and limited efficacy. By targeting specific brain regions involved in seizures, this approach has the potential to enhance therapeutic outcomes, minimize toxicity, and offer more personalized care. If successful, it could pave the way for new standards in neurological therapies, benefiting patients with drug-resistant epilepsy and reducing healthcare burdens through fewer hospitalizations and improved quality of life. This innovation aligns with broader trends in precision medicine, highlighting how advanced medical technologies can transform chronic disease management.